Core Viewpoint - Surrozen, Inc. (SRZN) has experienced significant selling pressure, resulting in a 29.7% decline over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - SRZN's current RSI reading is 27.4, suggesting that the heavy selling may be exhausting, which could lead to a price rebound [5] Group 2: Fundamental Indicators - There has been a strong consensus among sell-side analysts to raise earnings estimates for SRZN, resulting in a 69.2% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [6] - SRZN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7]

Core Viewpoint - AZUL has experienced significant selling pressure, declining 57.1% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory, supported by positive earnings forecasts from Wall Street analysts [1]. Group 1: Stock Performance - AZUL's stock has declined 57.1% in the last four weeks, indicating substantial selling pressure [1]. - The stock's Relative Strength Index (RSI) is currently at 23.35, suggesting it is oversold and may soon experience a trend reversal [5]. Group 2: Analyst Sentiment - There is strong consensus among sell-side analysts that AZUL will report better earnings than previously predicted, with the consensus EPS estimate increasing by 8.3% over the last 30 days [7]. - AZUL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

Core Viewpoint - HealthStream (HSTM) has experienced a significant downtrend, with a 13.2% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1] Group 1: Stock Performance - HSTM's stock has faced heavy selling pressure, leading to a decline of 13.2% in the last month [1] - The stock's Relative Strength Index (RSI) is currently at 25.2, indicating it is oversold and may soon reverse its trend [5] Group 2: Analyst Sentiment - There is a strong consensus among sell-side analysts regarding HSTM's ability to exceed previous earnings estimates, with a 0.5% increase in the consensus EPS estimate over the last 30 days [7] - HSTM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a favorable outlook for a potential rebound [8]

Core Insights - The communication services sector has several oversold stocks, presenting potential buying opportunities for undervalued companies [1][2] Company Summaries - **Fubotv Inc (FUBO)**: Reported a revenue of $405.96 million for the quarter, an 8.1% year-over-year increase, but missed the analyst consensus estimate of $415.45 million. The stock fell approximately 20% in the past five days, with a 52-week low of $1.10. The RSI value is 26.9, and shares closed at $2.42, down 17.4% [7] - **Cable One Inc (CABO)**: Announced disappointing first-quarter results, with a significant drop in residential data subscribers. The stock decreased around 43% over the past five days, reaching a 52-week low of $150.00. The RSI value is 12.2, and shares closed at $152.51, down 42.4% [7] - **Anterix Inc (ATEX)**: Launched the AnterixAccelerator initiative with an investment of up to $250 million. The stock fell about 9% over the past month, with a 52-week low of $27.37. The RSI value is 28.6, and shares closed at $29.84, down 0.4% [7]

Core Viewpoint - Phibro Animal Health (PAHC) has experienced significant selling pressure, resulting in a 22.3% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) for PAHC is currently at 27.99, suggesting that the stock is oversold and may be nearing a price reversal due to exhausted selling pressure [5]. - RSI is a momentum oscillator that ranges from 0 to 100, with readings below 30 typically indicating that a stock is oversold [2][3]. Group 2: Fundamental Indicators - There is a consensus among sell-side analysts that earnings estimates for PAHC have increased by 0.1% over the last 30 days, which often correlates with price appreciation in the near term [7]. - PAHC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8].

Group 1 - Orchid Island (ORC) has experienced a significant downtrend, with a stock decline of 24.7% over the past four weeks due to excessive selling pressure [1] - The stock is currently in oversold territory, indicated by an RSI reading of 26.89, suggesting that the heavy selling may be exhausting itself and a rebound could occur [5] - Wall Street analysts have raised earnings estimates for ORC by 11% over the last 30 days, indicating a potential for price appreciation in the near term [7] Group 2 - ORC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [8]

Group 1 - Criteo S.A. (CRTO) has experienced a significant downtrend, with a stock decline of 21.2% over the past four weeks due to excessive selling pressure [1] - The stock is currently in oversold territory, indicated by an RSI reading of 29.99, suggesting that the heavy selling may be exhausting itself and a rebound could occur [5] - Wall Street analysts are optimistic about CRTO's earnings potential, with a consensus EPS estimate increase of 1.3% over the last 30 days, indicating a potential for price appreciation [7] Group 2 - CRTO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the likelihood of a near-term turnaround [8]

Group 1 - Genelux Corporation (GNLX) has experienced a significant decline of 29.7% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for GNLX is currently at 29.16, suggesting that the heavy selling pressure may be exhausting itself [5] - There is strong consensus among Wall Street analysts that GNLX will report better earnings than previously predicted, with a 33% increase in the consensus EPS estimate over the last 30 days [7] Group 2 - GNLX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]

Core Viewpoint - Acrivon Therapeutics, Inc. (ACRV) has experienced a significant decline of 52.8% over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2]. - ACRV's current RSI reading is 23.16, suggesting that the heavy selling pressure may be exhausting, indicating a possible bounce back towards equilibrium [5]. Group 2: Fundamental Analysis - There is a consensus among sell-side analysts that earnings estimates for ACRV have increased by 4.3% over the last 30 days, which typically correlates with price appreciation [6]. - ACRV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].

Group 1 - VERRA MOBILITY CORP (VRRM) has experienced a significant decline of 19.9% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for VRRM is currently at 29.9, suggesting that the heavy selling pressure may be exhausting, which could lead to a price rebound [5] - There is strong consensus among Wall Street analysts that VRRM will report better earnings than previously predicted, with a 3.7% increase in consensus EPS estimates over the last 30 days [7] Group 2 - VRRM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]